TCA
CYTK icon

Troluce Capital Advisors’s Cytokinetics CYTK Stock Holding History

Troluce Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$5.28M – 52
2024
Q3 		$5.28M Buy
100,000
+69,602
+229% +$3.88M 0.31% 46
2024
Q2 		$1.65M Buy
+30,398
New +$1.83M 0.16% 67

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Troluce Capital Advisors's CYTK Position: Q4 2024 in Review

Troluce Capital Advisors sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 100,000 shares — an estimated $5.28M sold.

Troluce Capital Advisors first reported a position in CYTK in Q2 2024 and held it in 2 quarters. The position peaked at $5.28M in Q3 2024. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Troluce Capital Advisors reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Troluce Capital Advisors sold 100,000 Cytokinetics shares in Q4 2024, an estimated $5.28M.
  • Troluce Capital Advisors first reported a position in Cytokinetics in Q2 2024 and held it in 2 quarters.
  • Troluce Capital Advisors's Cytokinetics position peaked at $5.28M in Q3 2024.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Troluce Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.